Hepatitis B Virus (HBV) Genotyping Plus Drug Resistance
Also known as: HBV Genotype, PreCore and Resistance, HBV Resistance Testing
Use
Data generated in the genotyping assay is subsequently analyzed for mutations in the reverse transcriptase gene of HBV associated with resistance to therapeutic agents, and if identified an interpretation of their clinical significance provided.
Special Instructions
For optimal results, centrifuge the sample within six hours of collection and transfer plasma/serum to a polypropylene screw-cap tube before freezing. Submit separate frozen specimens if multiple tests are requested to avoid delays.
Limitations
The assay may not yield successful results when the HBV viral load is below 500 IU/mL. Moreover, the test has not been cleared or approved by the FDA, but such clearance is deemed unnecessary by the FDA for this type of test.
Methodology
PCR-based (PCR)
Biomarkers
LOINC Codes
- 32366-7
- 54210-0
- 43279-9
- 30283-6
- 30288-5
- 56792-5
- 56791-7
- 41396-3
Result Turnaround Time
7-12 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
1.2 mL
Minimum Volume
600 μL
Container
Gel-barrier tube, yellow-top (ACD) tube, lavender-top (EDTA) tube or PPT
Collection Instructions
Centrifuge sample within six hours of collection, transfer plasma/serum to a polypropylene screw-cap tube and freeze.
Storage Instructions
Freeze.
Causes for Rejection
Quantity not sufficient for analysis; heparin/SPS plasma (wrong anticoagulant); gross hemolysis; specimen not frozen